Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Alexion Pharmaceuticals stock

Learn how to easily invest in Alexion Pharmaceuticals stock.

Alexion Pharmaceuticals Inc is a biotechnology business based in the US. Alexion Pharmaceuticals shares (ALXN) are listed on the NASDAQ and all prices are listed in US Dollars. Alexion Pharmaceuticals employs 3,837 staff and has a trailing 12-month revenue of around $6.3 billion.

How to buy shares in Alexion Pharmaceuticals

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ALXN – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Alexion Pharmaceuticals stock price (NASDAQ: ALXN)

Use our graph to track the performance of ALXN stocks over time.

Alexion Pharmaceuticals shares at a glance

Information last updated 2021-09-19.
Latest market close$177.12
52-week range$0.00 - $0.00
50-day moving average $182.75
200-day moving average $165.77
Wall St. target price$177.36
PE ratio 59.234
Dividend yield N/A (0%)
Earnings per share (TTM) $3.08

Buy Alexion Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 7 of 7
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, ETFs, Cryptocurrency
$0
$0
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
eToro
Stocks, ETFs, Cryptocurrency
$0
$10
8%-12% of your deposit
when you sign up and deposit at least $50. T&Cs apply.
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, TN, and HI.
Public
Stocks, ETFs, Cryptocurrency
$0
$0
Receive a free stock slice worth between $3–$300
when you sign up for an account and deposit at least $20.
Commission-free trading in stocks and ETFs with a social networking twist.
Tastyworks
Stocks, Options, ETFs, Cryptocurrency
$0
$0
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0
$0
$125 - $625
when you open and fund an account with $25,000 - $250,000+
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 3% interest on uninvested cash in your account with Robinhood Gold.
Tradier
Stocks, Options, ETFs
$0
$0
N/A
Customize your trade platform or build your own Deep tools, charts and screens Analyzers to help you study before you trade
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Alexion Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Alexion Pharmaceuticals price performance over time

Historical closes compared with the close of $177.12 from 2021-06-04

1 week (2022-09-19) N/A
1 month (2022-08-26) N/A
3 months (2022-06-26) N/A
6 months (2022-03-26) N/A
1 year (2021-09-26) N/A
2 years (2020-09-30) 54.78%
3 years (2019-09-30) 80.85%
5 years (2017-09-29) 26.25%

Is Alexion Pharmaceuticals stock undervalued or overvalued?

Valuing Alexion Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Alexion Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Alexion Pharmaceuticals's P/E ratio

Alexion Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 59x. In other words, Alexion Pharmaceuticals shares trade at around 59x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Alexion Pharmaceuticals's PEG ratio

Alexion Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.1706. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Alexion Pharmaceuticals's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Alexion Pharmaceuticals's EBITDA

Alexion Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $3.3 billion.

The EBITDA is a measure of a Alexion Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.

Alexion Pharmaceuticals financials

Revenue TTM $6.3 billion
Operating margin TTM 47.41%
Gross profit TTM $5.5 billion
Return on assets TTM 10.08%
Return on equity TTM 4.43%
Profit margin 10.89%
Book value $56.21
Market capitalisation $40.3 billion

TTM: trailing 12 months

Alexion Pharmaceuticals's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Alexion Pharmaceuticals.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

Alexion Pharmaceuticals's total ESG risk score

Total ESG risk: 28.21

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Alexion Pharmaceuticals's overall score of 28.21 (as at 01/01/2019) is pretty good – landing it in it in the 26th percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Alexion Pharmaceuticals is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

Alexion Pharmaceuticals's environmental score

Environmental score: 8.12/100

Alexion Pharmaceuticals's environmental score of 8.12 puts it squarely in the 9th percentile of companies rated in the same sector. This could suggest that Alexion Pharmaceuticals is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Alexion Pharmaceuticals's social score

Social score: 17.78/100

Alexion Pharmaceuticals's social score of 17.78 puts it squarely in the 9th percentile of companies rated in the same sector. This could suggest that Alexion Pharmaceuticals is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Alexion Pharmaceuticals's governance score

Governance score: 15.31/100

Alexion Pharmaceuticals's governance score puts it squarely in the 9th percentile of companies rated in the same sector. That could suggest that Alexion Pharmaceuticals is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Alexion Pharmaceuticals's controversy score

Controversy score: 2/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. Alexion Pharmaceuticals scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Alexion Pharmaceuticals has, for the most part, managed to keep its nose clean.

Environmental, social, and governance (ESG) summary

Alexion Pharmaceuticals Inc was last rated for ESG on: 2019-01-01.

Total ESG score 28.21
Total ESG percentile 26.48
Environmental score 8.12
Environmental score percentile 9
Social score 17.78
Social score percentile 9
Governance score 15.31
Governance score percentile 9
Level of controversy 2

Alexion Pharmaceuticals share dividends

We're not expecting Alexion Pharmaceuticals to pay a dividend over the next 12 months.

Have Alexion Pharmaceuticals's shares ever split?

Alexion Pharmaceuticals's shares were split on a 2:1 basis on 23 May 2011. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Alexion Pharmaceuticals shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Alexion Pharmaceuticals shares which in turn could have impacted Alexion Pharmaceuticals's share price.

Alexion Pharmaceuticals share price volatility

Over the last 12 months, Alexion Pharmaceuticals's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".

ALXN.US volatility(beta: 1.26)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Alexion Pharmaceuticals's is 1.2595. This would suggest that Alexion Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Alexion Pharmaceuticals overview

Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq for patients with hypophosphatasia; Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency; and Andexxa, a reversal agent for patients treated with rivaroxaban or apixaban. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG, NMOSD, ALS, COVID-19, and HSCT-TMA; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1820 that is in Phase I clinical trial, a therapeutic antagonist of properdin; and ALXN1720, which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 that is in Phase III clinical trials for the treatment of Wilson disease; ALXN1830, which are in Phase I clinical trials for neonatal Fc receptor; ALXN2040 and ALXN2050 to treat diseases associated with dysregulation of the complement alternative pathway; ALXN1850, an enzyme replacement therapy; ALXN2060 for treating transthyretin amyloidosis; and ALXN2075 for treatment of relapsed/refractory chronic lymphocytic leukemia. The company serves distributors, pharmacies, hospital, hospital buying groups, and other healthcare providers in the United States and internationally.

Frequently asked questions

What percentage of Alexion Pharmaceuticals is owned by insiders or institutions?
Currently 0.268% of Alexion Pharmaceuticals shares are held by insiders and 88.023% by institutions.
How many people work for Alexion Pharmaceuticals?
Latest data suggests 3,837 work at Alexion Pharmaceuticals.
When does the fiscal year end for Alexion Pharmaceuticals?
Alexion Pharmaceuticals's fiscal year ends in December.
Where is Alexion Pharmaceuticals based?
Alexion Pharmaceuticals's address is: 121 Seaport Boulevard, Boston, MA, United States, 02210
What is Alexion Pharmaceuticals's ISIN number?
Alexion Pharmaceuticals's international securities identification number is: US0153511094
What is Alexion Pharmaceuticals's CUSIP number?
Alexion Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 015351109

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site